Abstract
BackgroundTransurethral resection of the prostate (TURP) is the first choice for the treatment of benign prostatic hyperplasia. However, Transurethral split of prostate (TUSP) also seems to have clear clinical efficacy and clinical promotion value. To better clarify the potential and limitations of this treatment of prostate hyperplasia. This study objectively evaluated the clinical efficacy and safety of TUSP.MethodsThe Pubmed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Database for Chinese Technical Periodicals (VIP), Wanfang (Wanfang data), and SinoMed databases were searched for relevant studies. We then used Revman Manager 5.3 to perform a meta-analysis of all randomized controlled trials that evaluated the efficacy and safety of TUSP versus the classic surgical procedures commonly used in the clinic.ResultsA total of 7 studies involving 592 patients were included. The combined data showed that TUSP can shorten the operation time [MD: -33.68; 95% CI: − 38.45 to − 28.91; P < 0.001], reduce intraoperative blood loss [MD: -56.06; 95% CI: − 62.68 to − 49.43; P < 0.001], shorten the time of indwelling catheter [MD: -1.83; 95% CI: − 1.99 to − 1.67; P < 0.001], shorten the postoperative hospital stay length [MD: -1.61; 95% CI: − 1.90 to − 1.32; P < 0.001] and improved postoperative quality of life score (QOL) [MD: 0.16; 95% CI: 0.02 to 0.29; P = 0.02] compared to traditional surgical approaches. There were no statistically significant differences in international prostate symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine volume (RUV), or complications between TUSP and traditional approached.ConclusionTUSP can be an effective alternative for clinical treatment of benign prostatic hyperplasia. Given the limitations of the included studies, more high-quality randomized controlled trials are needed in the future to validate or update the results of this analysis.
Highlights
Transurethral resection of the prostate (TURP) is the first choice for the treatment of benign prostatic hyperplasia
The results showed that Transurethral split of prostate (TUSP) required a shorter time for surgery than traditional clinical surgery [mean difference (MD):-33.68; 95% Confidence interval (CI): − 38.45 to − 28.91; P < 0.001], but there was a large amount of heterogeneity (P < 0.001, I2 = 88%)
By reading the full text, we found that the study group underwent endoscopic observation of the surgical field after TUSP treatment, leading to prolonged operation time in the observation group, which may have resulted in heterogeneity
Summary
Transurethral resection of the prostate (TURP) is the first choice for the treatment of benign prostatic hyperplasia. Professor Guo Yinglu from the First Hospital of Peking University, China, has been working on the transurethral split of prostate (TUSP) method for many years and developed a variety of models of doublechambered water balloon expansion catheters. They standardized the surgical procedure, making the surgery more mature in the treatment of BPH, and proved that the operation is safe and effective through related research [7, 8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
